stockrow
Sunday 8 November 2026
Export MIRA’s income statement to Excel — free account
MIRA Pharmaceuticals, Inc.
MIRAHealthcare Drug Manufacturers General
- EPS
- +66.7%
- Free cash flow
- −50.8%
Quarter to June 2026, against a year earlier
0.57
0.03
+5.56%
Follow MIRA
Alert me
MIRA Pharmaceuticals, Inc. (MIRA) P/E ratio
MIRA Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MIRA MIRA Pharmaceuticals, Inc. | n/m |
| MDCX Medicus Pharma Ltd compare | n/m |
| SCLX Scilex Holding Company compare | n/m |
| AMRN Amarin Corporation PLC compare | n/m |
| GSK GSK PLC Sponsored ADR compare | 16.7× |
| OGN Organon & Co. compare | 17.3× |
| GRFS Grifols, S.A. compare | 18.2× |
| BIIB Biogen Inc. compare | 105× |
| NSRX Nasus Pharma Ltd. compare | — |
| Drug Manufacturers General industry median | 26.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)